Cytek® Biosciences Introduces the Cytek Orion™ Reagent Cocktail Preparation System, the First-of-its-Kind Automated Cocktail Preparation Instrument for Flow Cytometry
21 Diciembre 2023 - 8:00AM
Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis
solutions company, announced today the introduction of the Cytek
Orion™ reagent cocktail preparation system. Cytek’s new automated
reagent cocktailing technology simplifies and accelerates
laboratory workflow, assures consistent experimental results, saves
time and reduces the potential for errors.
Manually preparing reagent cocktails for flow
cytometry can be a time-consuming, error-prone process,
particularly when panels with more than six colors are being used.
The Cytek Orion system, a small, easy-to-operate, fully automated
reagent cocktail preparation instrument for flow cytometry,
eliminates the need for lab technicians to manually prepare
multicolor antibody cocktails for flow cytometry. With the Cytek
Orion system, users can mix and manage reagent cocktail
combinations of up to 60 individual reagent antibody
conjugates.
The Cytek Orion workflow is designed to fit
seamlessly with the Cytek ecosystem of complete solutions –
including its cloud-based platform, analyzers, sorter, reagents,
and software. It is instrument agnostic, enabling it to be used
with other systems as well.
Key features include:
- Accommodates antibody-conjugate
tubes with volumes of 0.5 mL to 2.0 mL per tube
- Up to 60 individual reagents can be
added per cocktail
- Aspirator can add 4 uL to 200 uL of
reagent to cocktail at the proper volume and concentration
- SpectroPrep™ software stores
information regarding reagents in a library for future use and can
provide an audit trail
- Users can mix up to three different
reagent cocktails per run
- Users can create cocktail recipes
and save for reuse, or use pre-programmed recipes for Cytek kits
and assays
Key benefits include:
- Hands-on time savings in the lab
due to walk away automation
- Reduces costs due to potential
human errors in cocktail preparation
- Decrease in repetitive motion
injuries when preparing high-color assays
“While other solutions enable everything from
washing to staining and more, the Cytek Orion system is unique in
that it is focused solely on cocktail making for sample
preparation,” noted Wenbin Jiang, Ph.D., CEO of Cytek Biosciences.
“This singular focus gives the Cytek Orion reagent cocktail
preparation system a smaller footprint and makes it ideal for
applications such as drug discovery that will use the same cocktail
multiple times. It also ensures that users are only paying for
features that they need – at a cost of approximately half that of
competitive solutions. The introduction of this unique new
preparation device moves the Cytek roadmap forward, expands our
suite of solutions for the cell analysis market and is expected to
broaden our reach into new markets.”
Please visit www.cytekbio.com for more
information.
About Cytek Biosciences,
Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading
cell analysis solutions company advancing the next generation of
cell analysis tools by delivering high-resolution, high-content and
high-sensitivity cell analysis utilizing its patented Full Spectrum
Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the
power of information within the entire spectrum of a fluorescent
signal to achieve a higher level of multiplexing with precision and
sensitivity. Cytek’s FSP platform includes its core instruments,
the Cytek Aurora™ and Northern Lights™ systems; its cell sorter,
the Cytek Aurora™ CS; the flow cytometer and imaging products under
the Amnis® and Guava® brands; and reagents, software and services
to provide a comprehensive and integrated suite of solutions for
its customers. Cytek is headquartered in Fremont, California with
offices and distribution channels across the globe. More
information about the company and its products is available at
www.cytekbio.com.
Cytek’s products are for research use only and
not for use in diagnostic procedures (other than Cytek’s Northern
Lights-CLC system and certain reagents, which are available for
clinical use in China and the European Union).
Cytek, Full Spectrum Profiling, FSP, Cytek
Aurora, Northern Lights, Cytek Orion, SpectroPrep, Amnis and Guava
are trademarks of Cytek Biosciences, Inc.
In addition to filings with the Securities and
Exchange Commission (SEC), press releases, public conference calls
and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn
page and X (formerly Twitter) account as channels of
distribution of information about its company, products, planned
financial and other announcements, attendance at upcoming investor
and industry conferences and other matters. Such information may be
deemed material information and Cytek may use these channels to
comply with its disclosure obligations under Regulation FD.
Therefore, investors should monitor Cytek’s website, LinkedIn page,
and X account in addition to following its SEC filings, news
releases, public conference calls and webcasts.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 as
contained in Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
which are subject to the “safe harbor” created by those sections.
All statements, other than statements of historical facts, may be
forward-looking statements. Forward-looking statements generally
can be identified by the use of forward-looking terminology such as
“may,” “might," "will,” “should,” “expect,” “plan,” “anticipate,”
“could,” “intend,” “target,” “project,” “contemplate,” “believe,”
“estimate,” “predict,” “potential” or “continue” or the negatives
of these terms or variations of them or similar terminology, but
the absence of these words does not mean that a statement is not
forward-looking. These forward-looking statements include
statements regarding Cytek’s new product launch, business plans and
market opportunities. These statements are based on management’s
current expectations, forecasts, beliefs, assumptions and
information currently available to management. These statements
also deal with future events and involve known and unknown risks,
uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from the
information expressed or implied by these forward-looking
statements. Factors that could cause actual results to differ
materially include risks and uncertainties such as those relating
to Cytek’s ability to manage the growth and complexity of its
organization; Cytek’s ability to manage relationships with key
customers and suppliers; Cytek’s ability to retain key employees;
Cytek’s ability to continue to stay in compliance with its material
contractual obligations, applicable laws and regulations; global
economic and market conditions; competition; and Cytek’s dependence
on certain sole and single source suppliers. You should refer to
the section entitled “Risk Factors” set forth in Cytek’s most
recent Quarterly Report on Form 10-Q filed with the SEC and other
filings Cytek Biosciences makes with the SEC from time to time for
a discussion of important factors that may cause actual results to
differ materially from those expressed or implied by Cytek’s
forward-looking statements. Although Cytek believes that the
expectations reflected in the forward-looking statements are
reasonable, it cannot provide any assurance that these expectations
will prove to be correct nor can it guarantee that the future
results, levels of activity, performance and events and
circumstances reflected in the forward-looking statements will be
achieved or occur. The forward-looking statements in this press
release are based on information available to Cytek as of the date
hereof, and Cytek disclaims any obligation to update any
forward-looking statements provided to reflect any change in its
expectations or any change in events, conditions, or circumstances
on which any such statement is based, except as required by law.
These forward-looking statements should not be relied upon as
representing Cytek’s views as of any date subsequent to the date of
this press release.
Media Contact:Stephanie
OlsenLages & Associates(949) 453-8080stephanie@lages.com
Investor Contact:Paul
GoodsonHead of Investor RelationsCytek
Biosciencespgoodson@cytekbio.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/4e723b4c-c539-4001-b94a-c9e74375c981
Cytek Biosciences (NASDAQ:CTKB)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Cytek Biosciences (NASDAQ:CTKB)
Gráfica de Acción Histórica
De May 2023 a May 2024